Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18 : prospective observational time-series and case-control studies
| العنوان: | Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18 : prospective observational time-series and case-control studies |
|---|---|
| المؤلفون: | Robert S. Heyderman, Dean Everett, Naor Bar-Zeev, Anne von Gottberg, Maaike Alaerts, Todd D. Swarthout, Jennifer R. Verani, Carina King, Neil French, Charles Mwansambo, Jacquline Msefula, Jane Mallewa, Stephen B. Gordon, Comfort Brown, Sithembile Bilima, Nigel A. Cunliffe, Cynthia G. Whitney |
| المساهمون: | VacSurv Consortium |
| المصدر: | The Lancet Global Health The Lancet Global Health, Vol 9, Iss 7, Pp e989-e998 (2021) The Lancet. Global Health |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Serotype, Malawi, Pediatrics, medicine.medical_specialty, wa_115, 030231 tropical medicine, Population, wa_395, Rate ratio, qw_806, Pneumococcal conjugate vaccine, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, education, Disease burden, education.field_of_study, business.industry, Incidence (epidemiology), Vaccination, qs_4, Case-control study, wc_217, Articles, General Medicine, Streptococcus pneumoniae, Human medicine, Public aspects of medicine, RA1-1270, business, medicine.drug |
| الوصف: | BACKGROUND\ud The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype invasive pneumococcal disease among vaccine-eligible-age and vaccine-ineligible-age children and adults.\ud \ud METHODS\ud We did a prospective observational time-series analysis and a case-control study. We used data from between Jan 1, 2006, and Dec 31, 2018, from laboratory-based surveillance at a government hospital in Malawi. This period included 6 years before and 7 years after introduction of PCV13. By use of negative-binomial regression, we evaluated secular trend-adjusted incidence rate ratio (IRR) in vaccine serotype and non-vaccine serotype invasive pneumococcal disease before and after introduction of PCV. We compared predicted counterfactual incidence in hypothetical absence of vaccine with empirically observed incidence following vaccine introduction. The case-control study assessed vaccine effectiveness, comparing PCV uptake among cases of vaccine-eligible-age invasive pneumococcal disease versus matched community controls.\ud \ud FINDINGS\ud Surveillance covered 10 281 476 person-years of observation, with 140 498 blood and 63 291 cerebrospinal fluid cultures. A reduction in total (vaccine serotype plus non-vaccine serotype) invasive pneumococcal disease incidence preceded introduction of PCV: 19% (IRR 0·81, 95% CI 0·74 to 0·88, p |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2214-109X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaec5b311d40e8181ed018c045e0637eTest https://hdl.handle.net/10067/1796830151162165141Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....aaec5b311d40e8181ed018c045e0637e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2214109X |
|---|